A Phase 1B Dose Escalation Trial of Human Anti 4 1BB Agonistic Antibody Utomilumab (PF 05082566) in Combination With Ado Trastuzumab Emtansine or Trastuzumab in Patients With HER2 Postive Advanced Breast Cancer
Latest Information Update: 21 Oct 2022
At a glance
- Drugs Trastuzumab (Primary) ; Trastuzumab emtansine (Primary) ; Utomilumab (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Adverse reactions
- 22 Sep 2022 The number of treatment arms increased from 2 to 4.
- 22 Sep 2022 Status changed to completed.
- 21 Jan 2021 Planned primary completion date changed from 1 Oct 2020 to 1 Feb 2021.